GLP-1s and the CPG Industry, Spring 2025

Are diet drugs about to upend grocery sales?

GLP-1 medications (Ozempic, Mounjaro, Wegovy, etc.) have reached a household penetration level at which their impact on grocery volumes can no longer be ignored. Big Chalk data shows 11.2% of adult U.S. consumers currently use a GLP-1; an additional 8.3% are considering a treatment plan in the next 12 months. 

The food industry could see a loss of between 1.2% and 2.9% of U.S. volume sold. Snacks and sweets brands might be particularly vulnerable.

Much like the Trade-Off Consumer – a large and important shopper segment many CPG brands fail to reach – GLP-1 users have few demographic skews but some characteristics that make them unique.

Learn more by downloading our July 2025 report.